Literature DB >> 10528857

Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression.

S Borrego1, M E Sáez, A Ruiz, O Gimm, M López-Alonso, G Antiñolo, C Eng.   

Abstract

Hirschsprung disease (HSCR) is a common genetic disorder presenting with functional intestinal obstruction secondary to enteric aganglionosis. HSCR can be familial or sporadic. Although five putative susceptibility genes have been identified, only germline mutations in the RET proto-oncogene account for a significant minority (up to 50%) of familial HSCR; 3% of sporadic HSCR in a population based series carry RET mutations. From 1998 to February 1999, we prospectively ascertained 64 cases of sporadic HSCR from the western Andalusia region. To determine if polymorphic sequence variants within RET could act as low penetrance predisposing alleles, we examined allelic frequencies at seven polymorphic loci in this population based series. Whether allele frequencies differed from those in the control population were determined by either chi-squared analysis or Fisher's exact test. For two sequence variants, A45A (c 135G-->A) (exon 2) and L769L (c 2307T-->G) (exon 13), the rarer polymorphic allele was over-represented among HSCR cases versus controls (p<0.0006). In contrast, two other polymorphisms, G691S (c 2071C-->A) (exon 11) and S904S (c 2712C-->G) (exon 15), were under-represented in the HSCR patients compared to controls (p=0.02). Polymorphisms in the RET proto-oncogene appear to predispose to HSCR in a complex, low penetrance fashion and may also modify phenotypic expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528857      PMCID: PMC1734238          DOI: 10.1136/jmg.36.10.771

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  22 in total

1.  A genetic study of Hirschsprung disease.

Authors:  J A Badner; W K Sieber; K L Garver; A Chakravarti
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

2.  The genetics of Hirschsprung's disease. Evidence for heterogeneous etiology and a study of sixty-three families.

Authors:  E Passarge
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

3.  Identity-by-descent and association mapping of a recessive gene for Hirschsprung disease on human chromosome 13q22.

Authors:  E G Puffenberger; E R Kauffman; S Bolk; T C Matise; S S Washington; M Angrist; J Weissenbach; K L Garver; M Mascari; R Ladda
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

4.  The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.

Authors:  M Santoro; R Rosati; M Grieco; M T Berlingieri; G L D'Amato; V de Franciscis; A Fusco
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

5.  Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin.

Authors:  T Nakamura; Y Ishizaka; M Nagao; M Hara; T Ishikawa
Journal:  J Pathol       Date:  1994-03       Impact factor: 7.996

6.  A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10.

Authors:  S Lyonnet; A Bolino; A Pelet; L Abel; C Nihoul-Fékété; M L Briard; V Mok-Siu; H Kaariainen; G Martucciello; M Lerone; A Puliti; Y Luo; J Weissenbach; M Devoto; A Munnich; G Romeo
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

7.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

Authors:  C Eng; D P Smith; L M Mulligan; M A Nagai; C S Healey; M A Ponder; E Gardner; G F Scheumann; C E Jackson; A Tunnacliffe
Journal:  Hum Mol Genet       Date:  1994-02       Impact factor: 6.150

8.  Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.

Authors:  G Romeo; P Ronchetto; Y Luo; V Barone; M Seri; I Ceccherini; B Pasini; R Bocciardi; M Lerone; H Kääriäinen
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

9.  Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.

Authors:  M Angrist; S Bolk; B Thiel; E G Puffenberger; R M Hofstra; C H Buys; D T Cass; A Chakravarti
Journal:  Hum Mol Genet       Date:  1995-05       Impact factor: 6.150

10.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.

Authors:  L M Mulligan; C Eng; T Attié; S Lyonnet; D J Marsh; V J Hyland; B G Robinson; A Frilling; C Verellen-Dumoulin; A Safar
Journal:  Hum Mol Genet       Date:  1994-12       Impact factor: 6.150

View more
  36 in total

1.  RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease.

Authors:  S Borrego; A Ruiz; M E Saez; O Gimm; X Gao; M López-Alonso; A Hernández; F A Wright; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

Review 2.  Hirschsprung disease, associated syndromes, and genetics: a review.

Authors:  J Amiel; S Lyonnet
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

3.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.

Authors:  Salud Borrego; Fred A Wright; Raquel M Fernández; Nita Williams; Manuel López-Alonso; Ramana Davuluri; Guillermo Antiñolo; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

4.  Novel sequence variants of the genes associated with the multiple endocrine neoplasia syndromes 1 and 2. analysis by an "in silico approach.".

Authors:  P Igaz; A Patócs; K Rácz
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

5.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

6.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

Authors:  V Neocleous; N Skordis; G Portides; E Efstathiou; C Costi; N Ioannou; M Pantzaris; V Anastasiadou; C Deltas; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

7.  Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.

Authors:  X-P Qi; R-B Ying; J-M Ma; W-T Liu; Z-F Du; J Fei; C-P Yang; Q-Z Song; H-Y Jin; Z-G Chen; J-S Han; J-Q Wang; X-L Chen; Y Zhao; J-J Lu; X-N Zhang
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

8.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

9.  Single nucleotide polymorphisms in the RET gene and their correlations with Hirschsprung disease phenotype.

Authors:  Robert Smigiel; Arleta Lebioda; Dariusz Patkowski; Jerzy Czernik; Tadeusz Dobosz; Karolina Pesz; Monika Kaczmarz; Maria M Sasiadek
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

10.  Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.

Authors:  Monique G Zaahl; Alison T Merryweather-Clarke; Maritha J Kotze; Schalk van der Merwe; Louise Warnich; Kathryn J H Robson
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.